08:00 - 12:00

LIVE SURGERY

AUDITORIUM

CHAIRS FROM AUDITORIUM:
Arpa P., Berrocal M., Morales Canton V., Nikolakopoulos A., Romano M., Williamson T.

CHAIRS FROM ORs:
Florence: D'Amico D.J., Dhawahir-Scala F., Rezaei K., Steel D.
Athens: Gotzaridis S., Parikakis S.

SURGEONS:
Florence: Patelli F., Bali E., Garcia Arumi J., Caretti L., Eckardt C., Claes C., Lanzetta P., Tognetto D., Rizzo S.
Athens: Sabrosa N.A., Nagpal M., Gotzaridis S., Vakalis T., Georgalas I.
Lugano: Pournaras J.A.

08:00 - 09:05

AMD: NEW DIAGNOSTIC AND TREATMENT STRATEGIES

ROOM VERDE

CHAIRS: Boscia F., Rosenfeld P.J., Singh R.

08:00 / Natural history of subclinical, non-exudative macular neovascularization in AMD
Rosenfeld P.J.
08:05 / Quantitative vascular density changes in choriocapillaris around CNV after anti-VEGF treatment: dark halo
Rispoli. M.
08:10 / A Comparison among different automated segmentation algorithms to assess neovascular AMD using Swept Source Optical Coherence Tomography Angiography
Parravano M.
08:15 / Discussion
08:20 / Early findings of Type 3 neovascularization with swept-source angio-oct
Nicolo M.
08:25 / Treat and extend anti-VEGF drugs regimen for neovascular AMD
Boscia F.
08:30 / Can we achieve quarterly dosing in exudative AMD?
Singh R.
08:35 / Discussion
08:40 / Bilateral therapeutic response to unilateral anti-VEGF injection in various diseases in neovascular AMD
Schwartz S.G.
08:45 / Non-responders to anti-VEGF therapy - How often do we see them? What to do?
Richard G.
08:50 / A new form of meta-analysis for ranibizumab and aflibercept dosing
Spaide R.F.
08:55 / Discussion

08:00 - 10:00

RETINAL DETACHMENT ADVANCED COURSE

ROOM ONICE

CHAIRS: Nadal J., Ogura Y., Regillo C., van Meurs J.

08:00 / Progression of retinal detachment
van Meurs J.
08:05 / Does the choroid play a role in retinal detachment progression?
Wolfensberger T.
08:10 / Muller cells genetic modulation and retinal detachment
Azzolini C.
08:15 / Macular Optical Coherence tomography findings after vitreoretinal surgery for rhegmatogenous retinal detachment
Coppola M.
08:20 / Discussion
08:25 / The role of scleral buckling in primary and complex retinal detachment repair: evidence and personal experience
Regillo C.D.
08:30 / Scleral buckling after LASIK surgery: practical considerations
Friberg T.
08:35 / Using the principle of buckling for retinal detachments in modern ways
Binder S.
08:40 / Discussion
08:45 / Phaco-combined vitrectomy for primary retinal detachment: a consecutive series of 340 cases in an ambulatory surgical center
Oshima Y.
08:50 / Primary retinal detachment: vitrectomy with air tamponade
Rapizzi E.
08:55 / Retinal detachment in Morning Glory Syndrome
Ferrara V.
09:00 / Discussion
09:05 / Safe gas bubble use in RD
Williamson T.
09:10 / Management of intrusion of buckle and recurrent RD
Soni M.
09:15 / Why I use heavy silicone oil?
Mateo C.
09:20 / Discussion
09:25 / How PVR surgery is changing
Nadal J.
09:30 / PPV for Rhegmatogenous Retinal Detachment in uveitis
Androudi S.
09:35 / Discussion

09:10 - 10:00

ENDOPHTHALMITIS

ROOM VERDE

CHAIRS: Faraldi F., Moisseiev J., Schwartz S.G., Zweifel S.

09:10 / Are the EVS guidelines for management of post-operative endophthalmitis still relevant?
Moisseiev J.
09:15 / Endopthalmitis treatment: earlier antibiotics, later diagnosis with improved PCR
van Meurs J.
09:20 / Medical and surgical management of fungal endophtalmitis
Chizzolini M.
09:25 / Endogenous endophtalmitis
Agrawal R.
09:30 / Discussion
09:35 / A new potential strategy for a 'resistance-free' preoperative prophylaxis
Franchini I.
09:40 / Leader 7 Study: new evidence in medical treatment after ophthalmic surgery
Bandello F.
09:45 / Needles and syringes as sources of silicone oil during intravitreal injection
Melo G.
09:50 / Endophthalmitis after intravitreal anti-VEGF injections: infection rates, prophylaxis, and distinguishing infectious endophthalmitis from non-infectious inflammation
Schwartz S.G.
09:55 / Discussion

10:00 - 11:00

FLUID CONTROL IN WET AMD

ROOM VERDE

10:00 / Pharmacological properties of intravitreal aVEGF agents: focus on innovative molecules
Danesi R.
10:15 / Disease activity assessment as driver of treatment: which parameters?
Viola F.
10:30 / How much can we dry the retina?
Staurenghi G.
10:45 / Innovation is on the horizon: new therapies in wAMD
Danesi R.

10:00 - 11:00

DME PATIENTS REAL LIFE EXPERIENCE WITH FLUOCINOLONE ACETONIDE FROM BOTH SIDES OF THE ATLANTIC

ROOM ONICE

MODERATOR: Bandello F.

10:00 / Three years data from Germany with fluocinolone acetonide
Augustin A.
10:15 / Advantage of continuous microdosing: San Raffaele hospital experience
Bandello F.
10:30 / US real world data with fluocinolone acetonide
Kim J.
10:45 / Discussion

10:00 - 11:00

ADAPTIVE OPTICS

ROOM 9

CHAIRS: Paques M., Sodi A.

10:00 / Clinical applications of adaptive optics ophthalmoscopy in 2019: a constellation of niches
Paques M.
10:10 / Standard clinical procedures for AOO using the rtx1 camera : photoreceptor and vessel imaging
Finocchio L.
10:20 / Surgical diseases observed by AOO: epiretinal membranes, retinal detachment, macular holes
Paques M.
10:30 / High resolution vascular imaging: static and dynamic
Castro Farias D.
10:40 / Microscopic diagnosis: the example of Fabry's disease
Sodi A.
10:50 / Adaptive Optics ophthalmoscopy in arterial hypertension
Rizzoni D.

11:00 - 13:00

FREE PAPERS - SURGICAL 2

ROOM ONICE

CHAIRS: Lesnoni G., Nikolakopulos A., Panozzo G., Schwart S.D.

1. NEGATIVE CORRELATION BETWEEN RETINAL DISPLACEMENT AND GANGLION CELL LAYER THICKNESS CHANGES IN EYES WITH EPIRETINAL MEMBRANE
   P. LOIUDICE, M. PELLEGRINI, A. MONTESEL, M. FIGUS, M. NARDI, G. CASINI
   
2. 25G VITRECTOMY WITH ERM AND MLI PEELING 30 DAYS AFTER DEXAMETHASONE IMPLANT IN PATIENTS WITH MACULAR PUCKER AND DIABETIC RETINOPATHY
   F. PIGNATELLI, G. ADDABBO
   
3. PREMACULAR HEMORRHAGE
   M. STAMENKOVIC, V. JAKSIC, A. BAJIC, B. VUKADINOVIC, N. NIKITOVIC, M. MAVIJA
   
4. HEADS-UP 3D VISION SYSTEM REDUCES ACUTE PHOTOTOXIC-RELATED AUTOFLUORESCENCE CHANGES AFTER MACULAR SURGERY
   C. LA SPINA, C. DEL TURCO, G. D'AMICO RICCI, D.C. GIOBBIO, C. PANICO
   
5. AN ANALYSIS OF CAPSULAR FLAPS USED FOR PERSISTENT FTMH
   W. ARMIN, D. VOGT, S. PRIGLINGER, R. SCHUMANN
   
6. RETINAL THICKNESS CHANGES AND FOVEA MIGRATION IN EYES WITH IDIOPATHIC MACULAR HOLE AFTER VITRECTOMY WITH HEMI-TEMPORAL INTERNAL LIMITING MEMBRANE PEELING
   J. KOGO, A. SHIONO, T. JUJO, H. TAKAGI
   
7. EFFECTIVENESS OF SUPERIOR INVERTED INTERNAL LIMITING MEMBRANE (ILM) FLAP IN MACULAR HOLE SURGERY: ANATOMICAL AND FUNCTIONAL OUTCOMES
   M.D.M. PRIETO DEL CURA, M.J. CRESPO CARBALLES, M. ACEBES GARCIA, J. GARCIA HINOJOSA
   
8. LAMELLAR MACULAR HOLES: WHEN IS SURGERY RECOMMENDED
   Schumann R.G.
   
9. AN ANALYSIS OF THE RESULTS OF PARS PLANA VITRECTOMY IN THE SURGICAL TREATMENT OF LAMELLAR MACULAR HOLES
   K. ZHOGOLEV, Y. BAYBORODOV, I. PANOVA
   
10. OCRIPLASMIN IN THE TREATMENT OF VITREOMACULAR TRACTION: A META-ANALYSIS OF DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS BASED ON SUBJECT-LEVEL DATA
    T. JACKSON, K. BLOT, B. LESCRAUWAET, L. DUCHATEAU, J. HALLER
    
11. PULSATILE RETINAL ARTERY MACROANEURYSM POST LASER HYALOIDOTOMY
    K. SRINIVASAN
    
12. FIRST IN HUMAN CLINICAL TRIAL OF ROBOT-ASSISTED SUBRETINAL DRUG DELIVERY UNDER LOCAL ANAESTHESIA
    J. KAPETANOVIC, K. XUE, T.L. EDWARDS, H.C.M. MEENINK, M.J. BEELEN, G.J.L. NAUS, M.D. DE SMET, R.E. MACLAREN
    
13. MICROSCOPE-INTEGRATED INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY-GUIDED INTERNAL LIMITING MEMBRANE PEELING WITH INVERTED ILM FLAP TECHNIQUE FOR MYOPIC TRACTION MACULOPATHY ASSOCIATED RETINAL DETACHMENT: A NOVEL TECHNIQUE
    A.K. KUMAR, D. AGARWAL, D. SUNDER
    
14. MYOPIC TRACTION MACULOPATHY: THE NEW ITALIAN STAGING SYSTEM (MISS)
    B. PAROLINI, M. PALMIERI, U. NAVA
    
15. SUBRETINAL INJECTION PLATELET-RICH PLASMA FOR HIGHLY MYOPIC FOVEOSCHISIS: TECHNIQUE AND OUTCOME
    V. ZOTOV
    
16. VITRECTOMY FOR OPTIC DISC PIT MACULOPATHY
    A. ALKALIBY
    
17. CLINICAL UTILITY OF INTRAOPERATIVE OCT IN VARIOUS OF POSTERIOR SEGMENT PATHOLOGIES
    A. SINGH, B. MOHARANA, B. TIGARI, R. SINGH
    
18. SURGICAL CHALLENGES OF BILATERAL RHEGMATOGENOUS ON TRACTIONAL RETINAL DETACHMENTS IN A MALAY PATIENT WITH PROLIFERATIVE DIABETIC RETINOPATHY
    M.B. BASTION
    
19. DIABETIC NIGHTMARE
    A. LA MANTIA, A. PIOPPO
    
20. EFFICACY OF INTRAOPERATIVE RANIBIZUMAB INJECTION WITH LONG-ACTING GAS INFUSION ON RECURRENCE OF VITREOUS HEMORRHAGE AFTER DIABETIC VITRECTOMY
    S. OZEN
    
21. PSEUDOPHAKIA PROTECTS AGAINST FELLOW EYE DIABETIC VITREOUS HAEMORRHAGE
    P. SCOLLO, Y. YANG, C. SVASTI-SALEE, N. DERVENIS, R.S.B. NEWSOM, L. SULLIVAN, D. HORNAN
    
22. PARS PLANA VITRECTOMY ENDORESECTION FOR INTRAOCULAR MEDULLOEPITHELIOMA
    G. PIERETTI, S. RIZZO, G. VICINI, C. NICOLOSI, D. MASSI, C. MAZZINI
    
23. ENDORESECTION AFTER A RU106 BRACHYTHERAPY FAILURE
    M.I. RELIMPIO LOPEZ, A. ALCANTARA SANTILLANA, M.J. DIAZ GRANDA, L. COCA GUTIERREZ, F. ESPEJO ARJONA, B. DOMINGUEZ GARCIA
    

11:00 - 12:00

TUMORS

ROOM VERDE

CHAIRS: Balestrazzi E., Damato B., Heimann H., Murray T., Wolfensberger T.

11:00 / Multimodal imaging in intraocular tumors
Scupola A.
11:05 / Does early treatment of choroidal melanoma have an influence on the rate of metastatic disease?
Heimann H.
11:10 / Choroidal tumour biopsy
Damato B.
11:15 / Discussion
11:20 / Surgery in ocular tumors (VHL, Melanoma, vasoproliferative)
Maia A.
11:25 / Role of vitreoretinal surgery in maximizing treatment outcome following complications after proton therapy for uveal melanoma
Wolfensberger T.
11:30 / Clinical outcome after Ru106 Brachytherapy or Gamma Knife radiosurgery in uveal melanoma
Mazzini C.
11:35 / Discussion
11:40 / Prevention and treatment of radiation maculopathy
Midena E.
11:45 / Treatment of exudative retinal vascular malformations
Mura M.
11:50 / Intraocular lymphoma: recognize and treat
Angi M.
11:55 / Discussion

12:00 - 13:00

HOW DO I DO IT: 3D VIDEO PANEL

AUDITORIUM

MODERATOR: EL Rayes E.

PANELIST: Avci R., Chow D., Claes C., Eckardt C., Garcia-Arumi J., Maia M., Nadal J., Rizzo S.

12:00 - 13:00

UVEITIS

ROOM VERDE

CHAIRS: Agrawal A., Androudi S., De Smet M., Vannozzi L.

12:00 / Inflammation or atrophy, this is the question
Accorinti M.
12:05 / A practical approach to retinal vasculitis
Cimino L.
12:10 / Diagnostic pars plana vitrectomy
Vannozzi L.
12:15 / Discussion
12:20 / Placoid maculopathies
Introini U.
12:25 / Ocular sarcoidosis: diagnostic update
Miserocchi E.
12:30 / Discussion
12:35 / Approach to Tuberculous uveitis
Agrawal R.
12:40 / Toxoplasmosis chorioretinitis: current treatments
De Smet M.
12:45 / Surgery for Infectious Retinitis When Medical Therapy is not Sufficient
Arevalo J.F.
12:50 / A novel vitreous surgery to remove intraocular cysticercosis
Natarajan S.
12:55 / Discussion

13:00 - 14:00

ALLERGAN SYMPOSIUM: TREATING DME: RECOMMENDATIONS FROM THE EXPERTS

AUDITORIUM

MODERATORS: Bandello F., Loewenstein A.

13:00 / Welcome and introduction
Bandello F., Loewenstein A.
13:02 / Unmet needs in treating DME in real life
Bandello F.
13:14 / Seeking consensus in DME management: findings from Germany
Augustin A.
13:26 / Real-world experience with dexamethasone implant
Maia M.
13:38 / Treating DME patients undergoing cataract surgery: 'tips and tricks'
Kupperman B.
13:50 / Discussion

13:00 - 14:00

ZEISS SYMPOSIUM: INNOVATION IN RETINAL DIAGNOSIS

ROOM VERDE

MODERATORS: Parravano M., Shah G.K., Staurenghi G.

13:00 / Next generation ultra-widefield angiography
Staurenghi G.
13:15 / Latest advancements in OCT Angiography and retina diagnostics part 1
Parravano M.
13:30 / Latest advancements in OCT Angiography and retina diagnostics part 2
Shah G.K.
13:45 / Discussion

13:00 - 14:00

BAUSCH+LOMB SYMPOSIUM: TRANSFORMING RETINAL SURGERY THROUGH PIONEERING TECHNOLOGY

ROOM ONICE

MODERATOR: Avitabile T.

13:00 / The Advantages of Dual Port Cutter technology
De Cilla S.
13:12 / From cutting to liquefaction
Le Mer Y.
13:24 / The learning curve of Hypersonic Vitrectomy
Bali E.
13:36 / Hypersonic Vitrectomy - Experimental study
Stanga P.
13:48 / Discussion

13:00 - 14:00

ALFA INTES SYMPOSIUM: INNOVATION IN VITREORETINAL SURGERY: A NEW MOLECULE OF BLUE

ROOM 9

CHAIRS: Pileri M.A., Romano M.

13:00 / A close look at a new Blue dye: an innovative recently developed molecule
Spadaro A.
13:10 / From preclinical development to clinical application
Romano M.
13:20 / Are all Intraocular dyes toxic? Safety of lutein-based dyes
Coppola M.
13:30 / ILM Peeling: when and why?

13:40 / New Trends in chromovitrectomy
Romano M.
13:50 / Discussion

13:00 - 14:00

OXURION SYMPOSIUM: UPDATE ON OCRIPLASMIN REAL WORLD EVIDENCE IN ITALY

ROOM 6

MODERATORS: Barca F., Cacciamani A., Cereda M.

13:00 / Introduction: overview of recent study data on ocriplasmin.
Barca F.
13:10 / Introduction: overview of recent study data on ocriplasmin. Experience from Careggi Hospital, Florence
Giuntoli M.
13:15 / Short term vitreous modifications following ocriplasmin. Experience from Bietti Foundation, Rome
Cacciamani A.
13:30 / Ocriplasmin for VMT: A look outside the macula. Experience from Sacco Hospital, Milan
Cereda M.
13:45 / Question & Answer: Critical patient selection criteria identified by real world evidence on ocriplasmin

13:00 - 14:00

SECOND SIGHT SYMPOSIUM: THE STANDARD OF CARE FOR RETINITIS PIGMENTOSA: THE EPI-RETINAL PROSTHESIS SYSTEM

ROOM 4

MODERATOR: Cinelli L.

13:00 / Long term results of the biggest Argus II patients center: benefits and complications
Cinelli L.
13:15 / Use of Intraoperative OCT in ensuring optimal array-retina contact during Argus II implantation surgery
Yoon Y.H.
13:30 / Epiretinal membrane removal in an Argus II implanted eye: functional results
Patelli F.
13:45 / Discussion

14:00 - 15:00

PROLIFERATIVE DIABETIC RETINOPATHY

AUDITORIUM

CHAIRS: Arevalo J.F., Bressler N., Le Mer Y., Stanga P.

14:00 / OCT-A and FA findings after anti-VEGF PDR treatment
Tadayoni R.
14:05 / Clinical highlights of DRCR Network treatment regimen for proliferative diabetic retinopathy
Bressler N.
14:10 / Can we predict which eyes with PDR do best with anti-VEGF vs PRP?
Bressler S.
14:15 / Anti-VEGF monotherapy for ischemic diabetic retinopathy: consequences of inadvertent treatment Interruptions
Johnson M.W.
14:20 / Discussion
14:35 / Pre-Operative Intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy
Arevalo J.F.
14:40 / Machines, settings and instrumentation for the new PDR vitrectomy
Morales-Canton V.
14:45 / Surgical Management of PDR advances in techniques are improving surgical outcomes
Berrocal M.
14:50 / Discussion

14:00 - 15:00

AIORAO COURSE: INSTRUMENTAL SEMEIOTICS FOR RETINAL DISEASE

ROOM ONICE

MODERATORS: Campos E., Drago D., Huang S., Lam L.

14:00 / Retcam imaging for Retinopathy of prematurity screening
Zavolini M.
14:05 / The orthoptic in the ocular electrophysiology clinic
Placidi G.
14:10 / Adaptive optics in ophtalmology; early diagnosis in retinal diseases
Cipollini F.
14:15 / Choroidal and retinal imaging with OCT
Biagini I.
14:20 / Microperimetry in macular diseases
Convento E.
14:25 / Discussion
14:35 / Electrophysiology and modern indications
Huang S.
14:40 / Wide-field Imaging In Pediatric Retinal Disease
Capone A.J.
14:45 / Innovations in Low Vision Rehabilitation
Lam L.
14:50 / Discussion

15:00 - 16:00

MACULAR HOLE

AUDITORIUM

CHAIRS: Awh C., Binder S., Boscia F., Devin F.

15:00 / Intraoperative OCT for difficult macular surgery
Binder S.
15:05 / Adaptive optics imaging of macular holes and epiretinal membranes: pre and post operatory evaluation of foveal healing
Paques M.
15:10 / When operating for macular hole, ERM and VMT: Combined phacovitrectomy vs vitrectomy and sequential cataract operation
Moisseiev J.
15:15 / Induced PVD with TPA and SF6 in patients with symptomatic VMT
Lafetà A.
15:20 / From combined phacovitrectomy to femtophacovitrectomy in macular surgery
Faraldi F.
15:25 / Discussion
15:30 / Autologous Platelet-rich plasma for myopic macular holes. Is it useful for Macular Holes with retinal detachment?
Figueroa M.
15:40 / Inverted flap for large idiopathic macular hole surgery: is there any advantage for the post-surgical remodelling of the outer retinal layers?
Bottoni F.
15:45 / Retinal relocation for large recurrent macular holes
Claes C.
15:50 / Autologous retinal transplant world experience
Mahmoud T.
15:55 / Amniotic membrane in macular hole surgery
Caporossi T.
16:00 / Discussion

16:00 - 16:15

FUTURE PERSPECTIVES IN OPHTHALMOLOGY

AUDITORIUM
Alcon, Allergan, Novartis

ALCON:
Michael Onuscheck (President, Global Business & Innovation)
ALLERGAN:
Montu Sumra (Executive Director, Medical Affairs, Eyecare)
NOVARTIS:
Joanne Chang (Worldwide Medical Affairs Head Ophthalmology)

16:40 - 17:20

DRY AMD by EURETINA

AUDITORIUM

CHAIRS: Rizzo S., Wolf S.

16:40 / Dry AMD classification
Staurenghi G.
16:45 / Impact of drusen and drusenoid retinal pigment epithelium elevation size and structure on RPE integrity
Schmidt-Erfurth U.
16:50 / Fluorescence lifetime imaging ophthalmoscopy in dry AMD
Wolf S.
16:55 / Adaptive optics in Dry AMD
Paques M.
17:00 / Recent advances in the management of Dry AMD
Querques G.
17:05 / The use of stem cells for retinal therapies
Da Cruz L.
17:10 / Amniotic membrane in Dry AMD
Rizzo S.
17:15 / Discussion

17:20 - 18:00

ARTIFICIAL INTELLIGENCE

AUDITORIUM

CHAIRS: Mahmoud T., Schmidt-Erfurth U., Tadayoni R., Williams G.A.

17:20 / Artificial Intelligence in retina: a constructive revolution
Schmidt-Erfurth U.
17:25 / How Artificial Intelligence improves insight into OCT-A imaging
Spaide R.F.
17:30 / Screening for AMD at home using Artificial Intelligence
Loewenstein A.
17:35 / Artificial Intelligence in diabetic retinopathy
Tadayoni R.
17:40 / Big data in the real world and Artificial Intelligence
Williams G.A.
17:45 / Artificial Intelligence in age-related macular degeneration - where are we? Where are we going?
Bressler N.
17:50 / Discussion

18:00 - 19:00

IMAGING

AUDITORIUM

CHAIRS: Bottoni F., Rosenfeld P.J., Spaide R., Staurenghi G.

18:00 / Comparison of ultrawide field technologies
Singh R.
18:05 / Wide-field imaging in pediatric retinal diseases
Capone A.J.
18:10 / Wide-field OCT vs ultrawide field fluorescein angiography for the assessment of retinal vasculopathies
Tadayoni R.
18:15 / OCT angiography vs dye-based angiography in neovascular choroidal diseases
Staurenghi G.
18:20 / Discussion
18:25 / What is a treatment-naive quiescent type 1 macular neovascularization really?
Querques G.
18:30 / New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings
Spaide R.F.
18:35 / Imaging of the choroidal vasculature using SS-OCT
Rosenfeld P.J.
18:40 / SS-OCT angiographic imaging of the choriocapillaris in macular diseases
Rosenfeld P.J.
18:45 / OCT angiography and macular function
Midena E.
18:50 / Discussion